Customized Antibiotic Treatment Duration Among Hospitalized Patients With Moderately Severe Community-Acquired Pneumonia

• Status: Not yet recruiting
• Trial end date: 2026-11-01

Summary

The primary objective of the study is to evaluate if the efficacy of an experimental strategy on antibiotic treatment duration based on stopping treatment when stability criteria are reached after at least 48 h of treatment, is non-inferior to the efficacy of standard antibiotic duration in CAP patients treated in the hospital setting.

As the secondary objectives, the study aims

• To study if the efficacy of our experimental strategy on antibiotic treatment duration compared to standard of care in CAP patients treated in the hospital setting is non-inferior in terms of:

• Persistence of cure at Day 30 of antibiotic treatment

• All-cause mortality rate on Day 30 of antibiotic treatment

• Patients evolution of pneumonia symptoms and quality of life via 2 scores (CAP score, CAP Sym) at Day 0 of treatment (retrospectively), at stability (Day S), at Day 7 , at Day 15, and at Day 30 of antibiotic treatment.

• To compare between the 2 study arms at Day 30 of antibiotic treatment:

• The duration of antibiotic treatment;

• The length of hospital stay;

• The frequency and severity of adverse events during the 30 days after the start of treatment.

• To explore the impact of reduced antibiotic treatment duration for CAP on the oropharyngeal resistome.

• Phase: Phase 3

Details

• Lead Sponsor: Assistance Publique - Hôpitaux de Paris
• Treatments: Anti-Bacterial Agents; Anti-Infective Agents